Gross ME - Search Results

1

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.

Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. Dorff TB, et al. Among authors: gross me. Prostate Cancer Prostatic Dis. 2014 Dec;17(4):359-65. doi: 10.1038/pcan.2014.37. Epub 2014 Sep 23. Prostate Cancer Prostatic Dis. 2014. PMID: 25245366 Free PMC article. Clinical Trial.

2

Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.

Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. Shazer RL, et al. BJU Int. 2006 Apr;97(4):691-7. doi: 10.1111/j.1464-410X.2006.05974.x. BJU Int. 2006. PMID: 16536755 Clinical Trial.

3

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Rosenberg JE, et al. Cancer. 2007 Aug 1;110(3):556-63. doi: 10.1002/cncr.22811. Cancer. 2007. PMID: 17577218 Free article. Clinical Trial.

4

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.

Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. Gross M, et al. BMC Cancer. 2007 Jul 27;7:142. doi: 10.1186/1471-2407-7-142. BMC Cancer. 2007. PMID: 17662137 Free PMC article. Clinical Trial.

5

Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.

Gross M, Ramirez C, Luthringer D, Nepomuceno E, Vollmer R, Burchette J, Freedland SJ. Gross M, et al. Prostate. 2009 Apr 1;69(5):520-7. doi: 10.1002/pros.20901. Prostate. 2009. PMID: 19107851

6

Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.

Mink SR, Hodge A, Agus DB, Jain A, Gross ME. Mink SR, et al. Among authors: gross me. Prostate. 2010 Aug;70(11):1201-10. doi: 10.1002/pros.21155. Prostate. 2010. PMID: 20564426

7

Show us a sign: the search for "game changing" prostate cancer biomarkers.

Quinn D, Gross M. Quinn D, et al. Lancet Oncol. 2011 Mar;12(3):204-6. doi: 10.1016/S1470-2045(11)70003-1. Lancet Oncol. 2011. PMID: 21310657 No abstract available.

8

The epothilones: new therapeutic agents for castration-resistant prostate cancer.

Dorff TB, Gross ME. Dorff TB, et al. Among authors: gross me. Oncologist. 2011;16(10):1349-58. doi: 10.1634/theoncologist.2010-0014. Epub 2011 Sep 30. Oncologist. 2011. PMID: 21964003 Free PMC article. Review.

9

Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.

Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O. Bahn D, et al. Among authors: gross me. Eur Urol. 2012 Jul;62(1):55-63. doi: 10.1016/j.eururo.2012.03.006. Epub 2012 Mar 21. Eur Urol. 2012. PMID: 22445223

10

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI. Jadvar H, et al. Among authors: gross me. Clin Nucl Med. 2012 Jul;37(7):637-43. doi: 10.1097/RLU.0b013e318252d829. Clin Nucl Med. 2012. PMID: 22691503 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters